STOCKS TELEGRAPH

Tag: CV

  • 3 Stocks Gearing Up for a Potential Rally: Cardiol Therapeutics (CRDL), CapsoVision (CV), Petmed Express (PETS)

    3 Stocks Gearing Up for a Potential Rally: Cardiol Therapeutics (CRDL), CapsoVision (CV), Petmed Express (PETS)

    The pharmaceutical industry faces an era of unprecedented change, where scientific breakthroughs are only part of the equation. In an environment of stricter budgets and rising stakeholder expectations, companies are under pressure to demonstrate tangible results quickly. Sustainable growth now hinges on careful allocation of resources, streamlined development pipelines, and early engagement with regulatory authorities to ensure both compliance and credibility.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is progressing toward a potential inflection point as its lead clinical program advances through late-stage development. With increasing visibility into trial execution and enrollment timelines, the company is steadily moving closer to key milestones that could significantly influence its valuation.

    Market Momentum

    As of May 5, 2026, CRDL closed at $1.31, down 1.50%, with trading volume (428,133 shares) below its average of 686,711 shares—suggesting moderate selling pressure without heightened volatility. With a market cap of $146.301M and a beta of 0.43, the stock continues to demonstrate relatively stable trading behavior. It remains within its 52-week range ($0.8800–$1.71), while a 1-year target estimate of $7.49 reflects substantial upside potential tied to upcoming clinical catalysts.

    Clinical Progress: MAVERIC Trial

    The Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis has reached approximately 75% patient enrollment, representing a key milestone toward completion. The trial is randomized, double-blind, and placebo-controlled, and was designed in collaboration with the FDA following Phase II discussions. To support timely enrollment, the company plans to activate additional U.S. clinical sites, with full enrollment expected by late Q2 or potentially extending into Q3 2026.

    Clinical Foundation

    The MAVERIC study builds on encouraging Phase II data, which demonstrated significant reductions in pain, inflammation, and recurrence rates. These results provide a strong clinical foundation and increase confidence in the likelihood of positive Phase III outcomes.

    Outlook

    With enrollment nearing completion, Cardiol is approaching a key catalyst window. Positive Phase III data could support regulatory advancement and act as a major driver of valuation re-rating.

    CapsoVision Inc (CV)

    CapsoVision Inc (NASDAQ: CV) started the day on May 05, 2026, with a price decrease of -0.14% at $7.06. During the day, the stock rose to $7.41 and sank to $6.73. Taking a more long-term approach, CV posted a 52-week range of $3.43-$15.37.

    Nevertheless, the stock’s Earnings Per Share (EPS) this year is 53.40%. This publicly-traded company’s shares outstanding now amount to $46.87 million, simultaneously with a float of $27.48 million. The organization now has a market capitalization of $351.86 million. Its Quick Ratio in the last reported quarter now stands at 3.09.

    Petmed Express Inc (PETS)

    As of May 05, 2026, Petmed Express Inc (NASDAQ: PETS) got off with the flyer as it spiked 4.41% to $2.37. During the day, the stock rose to $2.43 and sank to $2.25. Taking a long-term approach, PETS posted a 52-week range of $1.57-$4.32.

    Nevertheless, the stock’s Earnings Per Share (EPS) this year is -1033.33%. This publicly-traded company’s shares outstanding now amount to $21.38 million, simultaneously with a float of $14.73 million. The organization now has a market capitalization of $50.72 million. Its Quick Ratio in the last reported quarter now stands at 0.66.

  • Cemtrex, Inc. (CETX) Stock Among Stocks Being Targeted in Resurgence of Meme Stock Phenomenon

    Cemtrex, Inc. (CETX) Stock Among Stocks Being Targeted in Resurgence of Meme Stock Phenomenon

    Cemtrex, Inc. (CETX) stock prices continue their upward trend, having ended the July 9th, 2021 trading day at USD$1.49, a 13.64% increase. Subsequent premarket fluctuations have seen the stock rise another 15.44%, bringing it up to USD$1.72.

    Revenue Reports

    CETX reported USD$9.3 million in revenue for the quarter ended March 31st 2021, representing a year-over-year decrease of 24% from the USD$12.1 million reported for the same time period of 2020. The yearly difference is largely attributable to the devastating effects resulting from the onset of the coronavirus pandemic causing shutdowns and the limiting of business operations. The Advanced Technologies segment revenues for the quarter were down 11% to USD$5.5 million, while the Industrial Services segment revenues were down 36% to USD$3.8 million.

    Net Income Improvements

    Net income for the quarter was reported at USD$2.5 million for the quarter, up significantly from the net loss of USD$1.6 million reported in the prior year quarter. This year-over-year difference is largely attributable to various income items exclusive to the 2021 quarter, including a one-time settlement agreement, as well as unrealized gains on marketable securities.

    Traded Volume Increase

    The company reported cash and cash equivalents in the amount of USD$15.6 million as of March 31st 2021, indicating a comfortable liquidity position. Nevertheless, the steep climb of volume of shares traded from the low thousands to upwards of one million over a course of days is not adequately contextualized by the company’s recent financials. Rather, the absence of any other recent news or changes in fundamentals makes the stocks recent activity highly contentious.

    Meme Stock Phenomenon

    In the absence of recent developments, it seems likely that the stock finds itself the target of the meme stock phenomenon that has been captivating the markets again as of late. Driven by retail investors, the movement has seen underdog companies being targeted for a short-term pump and dump. Companies that indicate a high short interest find their stock prices being inflated artificially with little to no reason in the coordinated short squeeze. Rife with inherent risk and volatility, the movement is not consistent or reliable. Moreover, in most cases it seems a very large correction on a very short timeframe.

    Future Outlook for CETX

    Nevertheless, armed with the fortuitous surge in equity value provides the company the exposure to capitalize on the addition opportunities it finds at its disposal. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate more organic growth over the long term.